Palisade Bio, Inc. (PALI) Stock Price & Analysis
Palisade Bio, Inc. (PALI) fell 2.87% to USD 1.69 as of June 10, 2026 at 03:27 UTC, according to Nexqual real-time market data.
PALI last closed at USD 1.74; the session ranged USD 1.64–1.76 on volume of 1,702,320 shares. Market capitalization is $293.69M, with a 52-week range of USD 0.53–2.86 (NCM). Source: Nexqual, June 10, 2026 at 03:27 UTC.
Key Statistics (as of June 10, 2026 at 03:27 UTC)
| Price | USD 1.69 |
|---|---|
| Change | ▼ 2.87% (down) |
| Previous Close | USD 1.74 |
| Open | USD 1.75 |
| Day Range | USD 1.64 – 1.76 |
| 52-Week Range | USD 0.53 – 2.86 |
| Volume | 1,702,320 shares |
| Market Cap | $293.69M |
| Exchange | NCM |
Technical Analysis (PALI)
Nexqual's technical model rates PALI "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 33.27 (neutral) |
| vs SMA50 | Below (USD 1.99) |
| MACD | -0.05 (negative) |
Analyst Ratings (PALI)
Wall Street analysts rate PALI "None" based on 7 analysts, with a mean price target of USD 9.71 (range USD 5–25), per Nexqual as of June 10, 2026 at 03:27 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 9.71 |
| High Target | USD 25 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (PALI)
| EPS Estimate | USD -0.05 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-09-30 | USD -0.38 vs est -0.27 ▼ miss |
| 2025-06-30 | USD -0.58 vs est -0.56 ▼ miss |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Financials & Fundamentals (PALI)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -36.40% |
| Current Ratio | 23.71 |
| Total Cash | $132.63M |
| Total Debt | $0 |
| Free Cash Flow | $-9.60M |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Financial Health Score (PALI)
Nexqual rates Palisade Bio, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $133M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$12M |
| Efficiency | Critical — ROE -36%, ROA -23.4% |
Ownership (PALI)
| Insider Ownership | +0.03% |
|---|---|
| Institutional Ownership | +93.46% |
| Shares Outstanding | 173.58M |
| Float | 128.36M |
| Short % of Float | +17.75% |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
Leadership (PALI)
Palisade Bio, Inc. is led by J. D. Finley (age 67), CEO, CFO & Director, per Nexqual as of June 10, 2026 at 03:27 UTC.
| CEO, CFO & Director | J. D. Finley (age 67) |
|---|---|
| President & Chief Medical Officer | Mitchell Lawrence Jones (age 48) |
Major Backers & Investors (PALI)
Notable institutional backers of Palisade Bio, Inc. include B Group, Inc. , Janus Henderson Group PLC, Octagon Capital Advisors LP, according to Nexqual as of June 10, 2026 at 03:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| B Group, Inc. | 6.58% |
| Janus Henderson Group PLC | 6.16% |
| Octagon Capital Advisors LP | 5.92% |
| Perceptive Advisors Llc | 5.14% |
| Ameriprise Financial, Inc. | 5.02% |
| Commodore Capital Lp | 4.14% |
| RA Capital Management, L.P. | 4.1% |
| Franklin Resources, Inc. | 3.33% |
Source: Nexqual, June 10, 2026 at 03:27 UTC.
From Palisade Bio, Inc.'s Latest SEC 10-K Filing (filed 2026-03-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States.
- Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Partnerships
- The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▲ 0% |
| KPRX | Kiora Pharmaceuticals, Inc. | USD 2.59 | ▲ 3.6% |
| REVB | Revelation Biosciences, Inc. | USD 1.04 | ▲ 5.05% |
| QNRX | Quoin Pharmaceuticals, Ltd. | USD 4.95 | ▲ 10.24% |
| RNAZ | TransCode Therapeutics, Inc. | USD 4.98 | ▼ 11.07% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:27 UTC. This page is informational and not investment advice.